A placebo controlled, randomised, double blind study to assess the safety and efficacy of multiple doses of oral flupirtine for the treatment of painful HIV-associated neuropathy.

Trial Profile

A placebo controlled, randomised, double blind study to assess the safety and efficacy of multiple doses of oral flupirtine for the treatment of painful HIV-associated neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Flupirtine (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Relevare Pharmaceuticals
  • Most Recent Events

    • 02 Sep 2010 Interim results (n=8) from the extension phase presented at the 13th World Congress on Pain. Six patients have received treatment for at least 4 months.
    • 02 Sep 2010 Results for the randomised part of the trial presented at 13th World Congress on Pain
    • 28 May 2010 Status changed from recruiting to completed, as results have been reported, according to a Relevare media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top